Introduction
Epidemiological studies have shown that tobacco smoking is a major causative factor for lung cancer (1) . Cigarette smoke has more than 4000 chemical constituents, and of those at least 43 are animal carcinogens, while some are known to be human carcinogens. Polycyclic aromatic hydrocarbons (PAHs), including benzo[a]pyrene (BP), aromatic amines, including 4-aminobiphenyl (4-ABP), tobacco-specific nitrosamines and free radical species may contribute to the carcinogenic and mutagenic activity of cigarette smoke (2) . Metabolic activation of potentially carcinogenic chemicals and the covalent binding of the reactive carcinogen metabolites to DNA are considered key events in tumour initiation (3EE5). CarcinogenEEDNA adduct formation results from the complex processes of carcinogen absorption, activation and detoxification as well as DNA repair and tissue turnover. CarcinogenEEDNA adduct formation constitutes the biologically effective dose resulting from carcinogen exposure. Because DNA adduct formation is considered necessary for carcinogenesis, measurement of human DNA adducts provides evidence of molecular dosimetry, genotoxicity and potential cancer risk.
Molecular dosimetry of human genotoxic exposure and determination of carcinogenEEDNA adducts have advanced substantially during the last two decades. The most frequently used methods for the detection of carcinogenEEDNA adducts include 32 P-postlabelling, immunoassays and immunohistochemistry, HPLC-electrochemical detection, mass spectrometry, fluorescence and phosphorescence spectroscopy and special combinations of separation and detection techniques (6, 7) . 32 P-Postlabelling and the immunoassays have several advantages for monitoring human exposure to the complex chemical mixture that comprises tobacco smoke. 32 P-Postlabelling has a broad specificity for bulky DNA adducts typically formed from aromatic compounds (8) . (AE)-7b,8a-Dihydroxy9a,10a-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene-7,8-diol 9,10-epoxideEEDNA (BPDEEEDNA) immunoassays, utilizing antisera elicited against DNA modified with BP, recognize chemically related PAHEEDNA adduct structures due to cross-reactivity of the antibody (9) . For qualitative DNA adduct analysis, immunochemical adduct enrichment followed by 32 P-postlabelling was applied successfully for detecting tobacco smoke-derived specific DNA adduct structures in human lung tissue (10) . Although DNA adduct methodologies are improving, the absolute quantification of DNA adducts in complex exposure situations is still a critical unresolved problem. Also, correlations between methods of different specificity may be ambiguous (11, 12) .
Two comprehensive reviews have been published recently on smoking-related DNA adducts and tobacco carcinogenesis (13, 14) . Despite the extensive research in the field, several major questions have remained unanswered. DNA adduct formation in lung tumour as compared with that in histologically normal lung has not been examined extensively. In addition, there are conflicting data regarding the relationship between DNA adduct formation in target and surrogate tissues, and there is virtually no information on the DNA adduct composition (i.e. formation of specific DNA adduct structures) in different tissues.
In the present paper we document bulky DNA adduct formation in lung tumour, distal lung tissue, bronchial tissue and peripheral blood lymphocytes taken from smoking and nonsmoking patients with lung malignancy. The DNA adduct levels have been determined by 32 P-postlabelling with nuclease P1 adduct enrichment. In addition, PAHEEDNA adduct levels have been determined in lung tumour and peripheral lung tissue by BPDEEEDNA CIA. The results elucidate smoking-related primary DNA damaging processes in lung, and the use of peripheral blood lymphocytes as surrogate tissue in molecular epidemiological studies of human genotoxic exposures to complex environmental mixtures.
Materials and methods

Study population
Samples of lung tumour and histologically normal peripheral lung tissue, normal bronchial tissue and peripheral blood were obtained with informed consent from a total of 85 Hungarian patients with lung malignancy that underwent lung resection. Matched sample sets of lung tumour, normal peripheral lung, normal bronchus and peripheral blood lymphocytes were available from 32 subjects. The most prevalent histological types of lung cancer were adenocarcinoma (n 42) and squamous cell carcinoma (n 28). Detailed information on smoking history was obtained from the patients by self-reporting. Based on our previously published results (15) , two broad smoking categories were defined in the present study.`Smokers' included those patients who were active smokers at time of the surgery and those who gave up smoking less than a year before surgery.`Non-smokers' included those patients who were neversmokers and those who stopped smoking 41 year before the lung surgery. Detailed demographic and histological information for the study population is given in Table I . Number of the DNA samples from each tissue type analysed by 32 P-postlabelling and BPDEEEDNA CIA are indicated in Table II .
Isolation of DNA Histologically normal bronchial tissue (30EE300 mg), normal peripheral lung tissue (100EE500 mg) and lung tumour tissue (20EE500 mg) were obtained and frozen within 2 h of dissection. The normal lung tissue sample was dissected from a distal peripheral area of the lobe that held the tumour, or occasionally from a different lobe, when pulmonectomy was performed. Peripheral blood lymphocyte fractions were isolated from 5 ml stabilized blood by gradient centrifugation on Ficoll-Paque Plus solution (Amersham Biosciences, Uppsala, Sweden). The tissue samples were stored at À80 C prior to DNA isolation. Cartilage was removed from the bronchial samples before tissue homogenization. Tissue homogenates were prepared in 10 mM EDTA. DNA was isolated by a phenolEEchloroform extraction procedure as described previously (16) .
Determination of bulky DNA adducts by 32 
P-postlabelling
Bulky DNA adducts were detected in DNA samples from lung tumour, normal lung, normal bronchial tissue and peripheral blood lymphocytes by the 32 P-postlabelling method combined with nuclease P1 adduct enrichment, essentially as described before (15) C for 3EE4 days. Radioactivity in the diagonal zones and individual spots, as well as in a blank area adjacent to the diagonal zone, was determined by Cerenkov counting of the excised areas of the thin-layer chromatographic maps. Background radioactivity of the blank area, corrected for the size of the excised adduct areas was subtracted from the radioactivity of the adduct areas. Quantification was calculated as described previously (15) , by using specific radioactivity value of the [g-32 P]ATP, determined from radioisotope labelling of dAp. To refine quantification, an in vitro-modified BPDEEEDNA standard [110 adducts/10 8 nucleotides (nt)] was used in duplicate as external standard in each radioisotope-labelling assay for normalization of the DNA adduct values of the biological samples to reduce inter-assay variability (17) . The standard was originally prepared for a 32 P-postlabelling international trial and was kindly provided by Dr F.Beland (NCTR, Arkansas) (17) . To obtain the normalized DNA adduct value for the test sample, the following formula was applied: normalized adduct value of the test sample (DNA adduct value of the test sample calculated from its radioactivity measurement Â known DNA adduct value of the BPDEEEDNA external standard)/DNA adduct value of the BPDEEEDNA external standard calculated from its radioactivity measurement. Two to four replicate analyses were performed with each human DNA sample b`S mokers' are defined as the combined group of current smokers and short-term former smokers: current smokers smoked until the lung surgery; short-term former smokers gave up smoking 51 year before surgery (1 week to 1 year). c`N on-smokers' are defined as the combined group of long-term former smokers and life-time non-smokers: long-term former smokers gave up smoking 41 year before surgery (2EE32 years). Determination of PAHEEDNA adducts by competitive BPDEEEDNA CIA PAHEEDNA adducts were determined in a subset of DNA samples from lung tumour and normal lung tissue samples by BPDEEEDNA CIA. There was insufficient DNA from bronchial tissue and peripheral blood lymphocytes for this assay. The BPDEEEDNA CIA was performed essentially as described by Divi et al. (12) . Microtitre plates were coated with BPDEEEDNA modified to 0.33%, while the BPDEEEDNA in the standard curve, the same standard used for the 32 P-postlabelling assay, was modified to 110 (7R)-N 2 -[10-(7b,8a9a-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene)-yl]-deoxyguanosine (BPdG) adducts/10 8 nt. Each microtitre plate well contained either 10 mg of sample DNA or, for the standard curve wells, 10 mg of carrier calf thymus DNA. This competitive assay also employed anti-BPDE-DNA (#31, bleed 8/16/78, 1:6 Â 10 6 dilution), biotinEEavidin amplification, CDP-Star substrate and Emerald II enhancer (Tropix, Bedford, MA). Luminescence was read by TR717 microplate luminometer (PE Applied Biosystems, Foster City, CA). Samples were assayed in triplicate wells on each microtitre plate, and on one or two microtitre plates, depending on the availability of DNA sample. The 50% inhibition for the BPDEEEDNA standard curve was 2.69 AE 0.22 fmol BPdG/well (mean AE SEM, n 17) and the detection limit using 10 mg of sample DNA was 1.1 AE 0.2 BPdG adducts/10 8 nt.
Statistical analysis
For calculations of the levels of DNA adducts measured by CIA, samples with values lower than the limit of detection were assigned a value half way between zero and the limit of detection. The statistical analyses were performed with GraphPad Prism 3.0 software. Tests used for statistical analysis included the MannEEWhitney test for assessing the difference of DNA adduct levels of each tissue type between smokers and non-smokers, one-way ANOVA for comparisons of the DNA adduct levels among the various tissues, and Spearman correlation test for calculating the correlation between DNA adduct levels measured in matched tissues or determined by the two methods. Two-tailed P values were calculated for the determination of statistical significance.
Results
Autoradiographic maps of the 32 P-postlabelled bulky DNA adducts Autoradiographic maps of the 32 P-postlabelled bulky DNA adducts from smokers' pulmonary tissues exhibited the diffuse diagonal zone of radioactivity, which is characteristic of complex PAH exposure, with occasional well-resolved separate spots. Examples are shown in Figure 1 . There was no apparent difference between the distributions of radioactivity in the maps of the tumours and of the normal lung or bronchus; however, the intensity of radioactivity was generally lower in the tumour tissue samples. DNA adduct maps from non-smokers', tissue samples usually contained less radioactivity in the diagonal zone. Compared with solid tissues, the DNA adduct maps of the peripheral blood lymphocytes more often contained relatively well-resolved discrete spots suggesting differences in specific DNA adduct content. Figure 1 shows typical autoradiographic adduct maps of matched tumour tissue, normal lung, bronchial tissue and peripheral blood lymphocytes from two smoking lung cancer patients.
Bulky DNA adducts, determined by 32 P-postlabelling, related to smoking status Levels of bulky DNA adducts, as determined by 32 P-postlabelling, were stratified by smoking status and are presented in Table III . Bulky DNA adduct levels exhibited large inter-individual variation, from 0.3 to 27.8 adducts/10 8 nt in smokers, and from 0.3 to 14.4 adducts/10 8 nt in non-smokers. Compared with nonsmokers, smokers had 1.7EE2.4-fold higher DNA adduct levels, detected by 32 P-postlabelling, in lung tumour, normal lung and normal bronchial tissues (P 5 0.02). In peripheral blood lymphocytes, there was no smoking-related increase in bulky DNA adducts.
A set of matched samples that included all four tissues was available for 17 smokers and 15 non-smokers for DNA samples analysed by 32 P-postlabelling ( Figure 2 ). The relative differences between tissues and assays were similar to values for the complete sample set shown in Table III . In the matched set of samples, DNA adducts in lung tumour, normal lung and bronchus were significantly higher in smokers compared with non-smokers (P 0.016, 0.0003 and 0.0006, respectively). In peripheral blood lymphocytes the difference between smokers and non-smokers was marginally significant (P 0.054). In the individually matched DNA sample sets, in general, there were similar relative differences in the DNA adduct levels as among the unmatched tissue samples.
PAHEEDNA adducts, determined by competitive BPDEEEDNA CIA, related to smoking status Levels of PAHEEDNA adducts, determined by competitive BPDEEEDNA CIA in lung tumour and normal lung tissue DNA, were stratified by smoking status and are presented in Table III . PAHEEDNA adduct levels exhibited large inter-individual variation, from 0.4 to 22.6 adducts/10 8 nt in smokers, and 0.4EE10.8 adducts/10 8 nt in non-smokers. Undetectable PAHEEDNA adduct levels were observed in 6% of samples. PAHEEDNA adduct levels were 1.2EE1.4-fold higher in lung tissues from smokers, compared with non-smokers, however, the smoking-related increase was not statistically significant.
DNA adduct levels found in individuals with different cancer type and gender In the two smoking categories, the DNA adduct levels in different tissues, determined by both 32 P-postlabelling and BPDEEEDNA CIA, were compared for adenocarcinoma and squamous cell carcinoma. For lung tumour in non-smokers by 32 P-postlabelling only the difference between DNA adducts in adenocarcinoma (2.3 AE 1.4 adducts/10 8 nt, n 14), and squamous cell carcinoma (3.9 AE 1.3 adducts/10 8 nt, n 6) was significant (P 0.036). For normal lung the same difference was not significant (P 0.067). There was no significant difference in the DNA adduct levels of any tissue, regardless of the method, between males and females after stratification for histological type and smoking category (data are not shown). C for 3EE4 days. 
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Correlation between DNA adduct levels in lung tumour and normal lung by 32 P-postlabelling and BPDEEEDNA CIA In the complete set of samples, for smokers and non-smokers combined, tumour tissues contained 1.6EE2.3-fold lower DNA adduct levels, compared with the corresponding normal lung tissue, by both 32 P-postlabelling and BPDEEEDNA CIA (Table III) . These relative differences were statistically significant for smokers by 32 P-postlabelling and BPDEEEDNA CIA, with P values of 50.001 and 0.0086, respectively. For non-smokers only CIA gave significantly lower (P 0.0001) DNA adduct values in lung tumour compared with normal lung. In the set of matched samples assayed by 32 P-postlabelling, the P value for the difference between lung tumour and normal lung DNA adduct levels was 50.001 for smokers (Figure 2 ). There was a statistically significant positive correlation between bulky DNA adduct levels, determined by 32 P-postlabelling in lung tumour and normal lung of smokers (Spearman correlation coefficient r 0.58, P 0.001, n 29) and non-smokers (r 0.70, P 0.0001, n 25). PAHEEDNA adducts, measured by BPDEEEDNA CIA in lung tumour and normal lung also show a statistically significant correlation between lung tumour and normal lung of smokers (r 0.49, P 0.003, n 34) and non-smokers (r 0.37, P 0.048, n 29).
Correlation between DNA adduct levels, determined by 32 P-postlabelling in normal lung or bronchial tissues and peripheral blood lymphocytes For the complete sample set (Table III) , bulky DNA adduct levels, determined by 32 P-postlabelling in smokers, werẽ 2-fold higher, in histologically normal lung and bronchial tissue compared with peripheral blood lymphocytes (P 5 0.05) ( Figure 3A and C) . In non-smokers, there was no remarkable difference in bulky DNA adduct levels between the normal lung or bronchial tissue compared with blood lymphocytes (Figure 3B and D) . For the combined population of smokers and non-smokers, there was a statistically significant positive correlation between bulky DNA adduct levels in normal lung and peripheral blood lymphocytes (r 0.45, P 0.006, n 36), as well as between normal bronchial tissue and peripheral blood lymphocytes (r 0.47, P 0.004, n 35). However, stratification by smoking revealed a statistically significant correlation between bulky DNA adduct levels in blood lymphocyte DNA and normal lung DNA in non-smokers (r 0.55, P 0.023) ( Figure 3B) , whereas no such correlation was observed in smokers (r 0.25, P 0.30) ( Figure 3A) . Bulky DNA adducts in bronchial tissue were correlated with those in blood lymphocytes in non-smokers (r 0.55, P 0.026) ( Figure 3D ) but not in smokers (r 0.31, P 0.20) (Figure 3C ).
Correlation between bulky DNA adduct values obtained by 32 P-postlabelling and PAHEEDNA adduct values obtained by competitive BPDEEEDNA CIA The only DNA samples subjected to PAHEEDNA adduct determination by BPDEEEDNA CIA were normal lung and lung tumour, as there was insufficient DNA from normal bronchus and lymphocytes. For those tissues, comparison of values obtained showed similar relative differences between the DNA adduct levels measured by both 32 P-postlabelling and BPDEEEDNA CIA. There were 50 lung tumour DNA samples and 62 normal lung DNA samples assayed by both methods. There was a weak positive correlation between the two methodologies for the same set of lung tumour DNA samples (P 0.054, Figure 4A) ; however, there was no correlation when normal lung DNA samples were measured by both methods (P 0.96). When the matched 50 normal lung samples were analysed for the correlation between the two methods ( Figure 4B ), the correlation did not change substantially (Spearman correlation coefficient r 0.11, P 0.45).
Discussion
This study is the first one, in which 32 P-postlabelling and BPDEEEDNA CIA were used together for the DNA adduct determinations in the same human DNA sample set. In the present study we compared carcinogenEEDNA adduct levels in lung tumour and normal lung tissue between smokers and nonsmokers, and determined the correlation between the tissues and the two DNA adduct methods. We also compared carcinogenEEDNA adduct levels in normal lung and bronchial tissue with those in peripheral blood lymphocytes, and established exposure dose-related correlation between them.
We have demonstrated lower DNA adduct levels in the lung tumour tissues than in the histologically normal tissues, in both smokers and non-smokers by both 32 P-postlabelling and immunoassay. In an earlier comparative study of lung tumour and non-tumour lung tissues by van Schooten et al. (18) , there was an indication of lower adduct levels in the tumour than in the normal tissue. Tang et al. (19) , however, did not detect significant difference between PAHEEDNA adduct levels of tumour and non-tumour tissues using a BPDEEEDNA ELISA. The difference between DNA adduct levels in tumour and histologically normal tissues may reflect changed transport of Fig. 2 . Levels of bulky DNA adducts, determined by 32 P-postlabelling in matched samples of lung tumour, normal lung, normal bronchus and peripheral blood lymphocyte DNA from smoking and non-smoking lung cancer patients. The figure consists of box and whisker plots, in which the boxes extend from the 25th percentile to the 75th percentile with a horizontal line at the median (50th percentile). The whiskers extend between the lowest and the highest values. By MannEEWhitney test the difference between smokers and non-smokers were significant for lung tumour (P 0.016), normal lung (P 0.0003), normal bronchus (P 0.0006), and lymphocytes (P 0.054). For smokers only, by one-way ANOVA with Bonferroni's multiple comparison post test for log-transformed adduct values, P values were 50.001 for lung tumour versus normal lung, 50.001 for lung tumour versus normal bronchus, 50.01 for normal lung versus lymphocytes, and 50.01 for normal bronchus versus lymphocytes. the xenobiotics into the tumour cells, altered metabolic capacity, altered DNA repair and/or`adduct-dilution' in the rapidly proliferating tumour. In the literature the relative differences in DNA adduct levels in the tumour and non-tumour tissues vary. In larynx (20, 21) , breast (22) , hepatocellular carcinoma (23), gastric adenocarcinoma (24) and intrahepatic cholangiocarcinoma (25) observations are inconsistent suggesting that the relative differences in aromatic DNA adduct formation in human tumour and corresponding non-tumour tissues are largely organ-specific.
Smoking-related elevation of bulky DNA adduct levels in human lung and in other solid tissues has been reported in many studies since the early 1990s (13EE15,26). The present investigation serves to confirm the published findings. However, smoking-related elevation of bulky DNA adduct levels in white blood cells is not consistent in the literature (27EE30). It is likely that leukocyte DNA adduct levels may be influenced not only by smoking, but also by PAH exposures from the ambient environment, as well as diet (31) .
Those few human biomonitoring studies that provide correlations between biomarkers of exposure in target and surrogate tissues are valuable for estimation of genotoxic doses in environmental and occupational exposure situations in healthy populations. We detected statistically significant positive correlation between bulky DNA adduct levels, determined by 32 P-postlabelling, in normal lung or bronchial tissues and peripheral blood lymphocytes in lung cancer patients, which supports the results by Wiencke et al. (32) . However, in our study population, after stratification for smoking status, it was only the non-smokers for whom the correlation was significant. Also in lung patients, a positive correlation was observed between smoking-related N7-methylguanineEEDNA adduct levels in normal bronchus and peripheral blood lymphocyte DNA (33) . No correlation was found between normal lung and white blood cell PAHEEDNA adducts by van Schooten et al. and Tang et al. (18, 19) . Other studies with human bronchoalveolar lavage cells (34) , nasal mucosa (35) , larynx (21) and skin (36) also suggest that the correlation between DNA adduct levels in white blood cells and the corresponding tissue may be influenced by the internal dose of the genotoxic agents. The dose-dependence of correlation is also supported by animal studies, in which linear doseEEresponse relationships were found for adduct formation at low dose treatments, and the saturation of DNA-binding potency occurred at high doses (37). The activation of a xenobiotic depends on the metabolic capacity of the corresponding tissues, which should be considered in doseEEresponse extrapolations from surrogate tissue to target tissue in risk assessment.
In molecular cancer epidemiology and in biomonitoring of human exposures to complex mixtures of PAHs, 32 P-postlabelling and immunoassays are the most suitable methods for DNA adduct detection. The present study is the first one in which both 32 P-postlabelling and BPDEEEDNA CIA are used for the same in vivo-modified human DNA samples. 32 P-Postlabelling has the advantage of high sensitivity for bulky DNA adducts, on the other hand, without prior chemical structure-selective adduct enrichment it is not suitable for the identification of specific DNA adduct structures. The BPDEEEDNA CIA is the most sensitive and reproducible BPDEEEDNA competitive immunoassay and the smallest amount of DNA is required for the determination by using the same rabbit antiserum as for the previous BPDEEEDNA immunoassays (12) . It detects BPDEEEDNA adducts in experimental samples following treatment with BP in vivo and in vitro, and is selective for PAHEEDNA adducts in tissues exposed to or treated with complex mixtures of PAHs. In the past, our laboratories and others applied and compared 32 P-postlabelling and BPDEEEDNA ELISA or DELFIA (dissociation-enhanced lanthanide fluoroimmunoassay) in biomonitoring studies of PAH-exposed populations (38EE41). 32 P-Postlabelling and the immunoassays resulted in similar qualitative evidence of the relative exposure differences among the compared groups in most of the studies (39EE41). In the present study, the same ranges of DNA adduct levels were obtained by both methods. The good agreement may largely be attributed to the fact that the same in vitromodified BPDEEEDNA adduct standard was used as external standard for normalization of the adduct levels (17) in each 32 P-postlabelling assay, and for the calibration standard curve in the CIA measurements.
32 P-Postlabelling was more sensitive than the BPDEEEDNA CIA for recognizing the effect of smoking status on the DNA adduct levels in the pulmonary tissues. The smoking-related increases in adduct levels were statistically significant for the DNA adduct values obtained by the 32 P-postlabelling assay, but were not statistically significant when measured by CIA. A similar methodology-dependent recognition of effect was observed by Culp et al. (42) who compared 4-ABPEEDNA adduct levels in human peripheral lung by immunochemical, 32 P-postlabelling and GC/MS detection. No difference in the DNA adduct levels was found comparing smokers and long-term ex-smokers when the DNA adduct levels were determined by 4-ABPEEDNA-specific immunoassay, but a statistically significant difference was shown when 32 Ppostlabelling was applied. Such method-dependent differences in the recognition of exposure categories may primarily originate from the dissimilar overall adduct specificity of the two assays and from the complexity of semi-quantification.
In earlier human biomonitoring studies in PAH-exposed study populations, there was a weak negative correlation or a lack of correlation between corresponding DNA adducts by 32 P-postlabelling and BPDEEEDNA ELISA, or DELFIA, using the same anti-BPDEEEDNA rabbit antiserum as for the present BPDEEEDNA CIA (39, 40) . That suggested differences in DNA adduct specificity of the two methods. In the present work, based on the significant positive correlation in lung tumour, and the lack of correlation in the normal lung, we should also consider the possibility of qualitatively different DNA adduct patterns in lung tumour and the normal lung.
In conclusion, lung tumour and normal lung contained higher DNA adduct levels in smokers than in non-smokers, which difference was statistically significant by 32 P-postlabelling and not significant by BPDEEEDNA CIA. The applied 32 P-postlabelling technique was more sensitive and had à finer resolution' for detecting smoking-related human exposure differences than the immunoassay. Significantly lower DNA adduct levels were detected in lung tumour tissue as compared with normal tissue by both DNA adduct methods. The lower DNA adduct levels in the tumour tissue may originate from the combination of rapid cell proliferation, lower metabolic capacity, altered DNA repair processes and cellular activities that may resemble multi-drug resistance. A statistically significant positive correlation was found between DNA adduct levels in lung tumour and normal lung by both DNA adduct methods. This finding suggests that it might be possible to approximate DNA adduct levels in this study population between normal lung and lung tumour using either 32 P-postlabelling or BPDEEEDNA CIA. Correlation between DNA adducts in lung tissue and in peripheral blood lymphocytes was observed only in non-smokers; the lack of correlation in smokers suggests significant differences in metabolism, and perhaps exposure dose in the two tissues. This finding implies that carcinogenEEDNA adduct formation in the peripheral blood lymphocytes, a potential surrogate for normal lung and bronchial tissues, may be used for exposure assessment for the lung tissues at low exposure conditions only. There was a positive correlation between the two DNA adduct methods in lung tumour tissues, and lack of correlation in normal tissue, which may suggest that qualitatively different DNA adduct patterns are formed in the tumour and in the normal lung tissue, respectively. Further studies are needed to better characterize the qualitative composition of the smoking-related DNA adducts in human lung tissues and white blood cells.
